Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 9/20 | 0.55 |
| ▸ | NOS1 | P29475 | 5/20 | 0.39 |
| ▸ | CASP7 | P55210 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | PAH | P00439 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7132437 | 0.89 | HPRT1 (0.60) | HPRT1NOS1CASP7HSD17B10USP2 | |
| SCHEMBL147641 | 0.85 | HPRT1 (0.67) | HPRT1NOS1CASP7HSD17B10USP2 | |
| SCHEMBL336072 | 0.84 | HPRT1 (0.55) | HPRT1NOS1CASP7HSD17B10USP2 | |
| SCHEMBL60630 | 0.84 | HPRT1 (0.57) | HPRT1NOS1CASP7HSD17B10USP2 | |
| Water SCHEMBL10601101 | 0.83 | HPRT1 (0.54) | HPRT1NOS1CASP7HSD17B10USP2 | |
| Ammonia Solution, Strong SCHEMBL10901621 | 0.83 | HPRT1 (0.54) | HPRT1NOS1CASP7HSD17B10USP2 | |
| SCHEMBL8896319 | 0.83 | HPRT1 (0.68) | HPRT1 | |
| SCHEMBL10643032 | 0.82 | HPRT1 (0.56) | HPRT1NOS1CASP7HSD17B10USP2 | |
| SCHEMBL6270124 | 0.82 | HPRT1 (0.60) | HPRT1 | |
| Phosphoric Acid SCHEMBL9471917 | 0.81 | HPRT1 (0.59) | HPRT1NOS1CASP7HSD17B10USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE38341-E1 | Method for electrokinetic delivery of medicaments | BIOPHORETIC THERAPEUTIC SYSTEMS, LLC | 2003-12-09 | — | — | US | claimed |
| US-20260137773-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | VIROMISSILE, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260102417-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CANCER | KEYZELL HOLDING S L (ES) | 2026-04-16 | — | — | US | disclosed |
| US-20260097116-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | VIROMISSILE, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-12419924-B2 | Methods for combining adoptive T cell therapy with oncolytic virus adjunct therapy | TVAX BIOMEDICAL I, LLC (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2024069344-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CANCER | Keyzell Holding S.L. (ES) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024011250-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | VIROMISSILE, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-20230233631-A1 | METHODS FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ADJUNCT THERAPY | TVAX BIOMEDICAL I, LLC | 2023-07-27 | — | — | US | disclosed |
| US-11633442-B2 | Methods for combining adoptive T cell therapy with oncolytic virus adjunct therapy | TVAX BIOMEDICAL I, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230008052-A1 | CLONAL STRAINS OF ATTENUATED VACCINIA VIRUSES AND METHODS OF USE THEREOF | GENELUX CORPORATION | 2023-01-12 | — | — | US | disclosed |
| EP-1137764-B1 | NEW MEDICAL USE OF GENE AND VECTOR ENCODING A MULTISUBSTRATE DEOXYRIBONUCLEOSIDASE | ZGENE AS (DK) | 2005-03-02 | — | — | EP | disclosed |
| US-6702705-B1 | Prodrugs activated by targeted catalytic proteins | IGEN INTERNATIONAL, INC. | 2004-03-09 | — | — | US | disclosed |
| US-6582947-B1 | Nucleotide sequences coding enzymatic polypeptide for use in the virus treatment of cancer and viral infection | BIO VICI (CH) | 2003-06-24 | — | — | US | disclosed |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | IGEN, INC. | 2003-05-22 | — | — | US | disclosed |
| EP-1137764-A1 | NEW MEDICAL USE OF GENE AND VECTOR ENCODING A MULTISUBSTRATE DEOXYRIBONUCLEOSIDASE | Biovici (CH) | 2001-10-04 | — | — | EP | disclosed |
| US-6258360-B1 | BENZOATE CONJUGATES; ANTITUMOR AGENTS | IGEN INTERNATIONAL, INC. | 2001-07-10 | — | — | US | disclosed |
| WO-2000036099-A1 | NEW MEDICAL USE OF GENE AND VECTOR ENCODING A MULTISUBSTRATE DEOXYRIBONUCLEOSIDASE | BIOVICI (CH) | 2000-06-22 | — | — | WO | disclosed |
| EP-0746336-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0746336-A4 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN INC (US) | 1996-07-26 | — | — | EP | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097116-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | IRF3, IFNAR1, CXCL10 | HPRT1 1365/4885NOS1 1427/4885CASP7 1344/4885 |
| US-20260102417-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CANCER | TACR1, TACR2, NPSR1 | HPRT1 3181/4885NOS1 896/4885CASP7 1008/4885 |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | HPRT1 1359/4885NOS1 2569/4885CASP7 88/4885 |
| US-20260137773-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | CASP9, TP53, CASP2 | HPRT1 3921/4885NOS1 2793/4885CASP7 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.